tradingkey.logo

Aquestive Therapeutics Inc <AQST.OQ> expected to post a loss of 17 cents a share - Earnings Preview

ReutersMay 2, 2025 12:20 PM
  • Aquestive Therapeutics Inc AQST.OQ AQST.O is expected to show a rise in quarterly revenue when it reports results on May 12 for the period ending March 31 2025

  • The Warren New Jersey-based company is expected to report a 1.5% increase in revenue to $12.231 million from $12.05 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Aquestive Therapeutics Inc is for a loss of 17 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Aquestive Therapeutics Inc is $9.00​, above​ its last closing price of $3.00. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.13

-0.14

-0.19

Missed

-40

Sep. 30 2024

-0.12

-0.13

-0.13

Met

-2.6

Jun. 30 2024

-0.13

-0.12

-0.03

Beat

75.8​

Mar. 31 2024

-0.08

-0.08

-0.17

Missed

-106.5

​​Dec. 31 2023

-0.08

-0.08

-0.11

Missed

-37.5

Sep. 30 2023

-0.11

-0.11

-0.03

Beat

73.5​

Jun. 30 2023

-0.12

-0.12

-0.10

Beat

15.3

Mar. 31 2023

-0.18

-0.19

-0.12

Beat

36.5

This summary was machine generated May 2 at 12:20 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI